Drugs / Etokimab
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03614923 | Nov 2018 → Sep 2020 | chronic rhinosinusitis | AnaptysBio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03533751 | Jun 2018 → Dec 2019 | atopic eczema | AnaptysBio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03469934 | Nov 2017 → Oct 2018 | — | AnaptysBio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02920021 | Jan 2017 → Mar 2018 | food allergy | AnaptysBio, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Etokimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03469934 ↗ |
| Known as | ANB-020 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297580 ↗ |
| Action | Inhibit | “Etokimab, an anti-IL-33 biologic” PMID 31723064 ↗ Nov 2019 |
| Modality | Monoclonal antibody | “Humanized monoclonal antibody, administered by intravenous infusion” NCT02920021 ↗ |
| Route | Intravenous | “Humanized monoclonal antibody, administered by intravenous infusion” NCT02920021 ↗ |
| Target | IL33 | “Etokimab, an anti-IL-33 biologic” PMID 31723064 ↗ Nov 2019 |